Azitra Inc (AZTR)

Currency in USD
0.2117
-0.0093(-4.21%)
Closed·
0.2060-0.0057(-2.69%)
·
AZTR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.21160.2211
52 wk Range
0.10002.3976
Key Statistics
Prev. Close
0.221
Open
0.2156
Day's Range
0.2116-0.2211
52 wk Range
0.1-2.3976
Volume
212.86K
Average Volume (3m)
11.31M
1-Year Change
-87.9596%
Book Value / Share
0.65
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZTR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.7750
Upside
+266.08%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Azitra Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.7750
(+266.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy4.00+1,789.47%13.32MaintainSep 24, 2025

Earnings

Latest Release
May 13, 2026
EPS / Forecast
-0.25 / -1.02
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AZTR Income Statement

Compare AZTR to Peers and Sector

Metrics to compare
AZTR
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.1x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.3x2.9x2.6x
Price / LTM Sales
-6.7x3.0x
Upside (Analyst Target)
266.1%115.1%58.6%
Fair Value Upside
Unlock9.3%10.2%Unlock

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
471.83K2.91%99.89K
Other Institutional Investors
75.91K0.47%16.07K
Public Companies & Retail Investors
15.64M96.62%3.31M
Total
16.19M100.00%3.43M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Geode Capital Management, LLC2.90%469,87899
UBS Asset Management AG0.19%30,2056

People Also Watch

11.9500
MNTS
-26.69%
19.0100
ASTC
-28.26%
1.7300
QUCY
-8.95%
39.4900
INHD
0.00%
1.290
QTEX
-15.13%

FAQ

What Is the Azitra (AZTR) Stock Price Today?

The Azitra stock price today is 0.2117 USD.

What Stock Exchange Does Azitra Trade On?

Azitra is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Azitra?

The stock symbol for Azitra is "AZTR."

What Is the Azitra Market Cap?

As of today, Azitra market cap is 3.4300M USD.

What Is Azitra's Earnings Per Share (TTM)?

The Azitra EPS (TTM) is -1.4305.

When Is the Next Azitra Earnings Date?

Azitra will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is AZTR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Azitra Stock Split?

Azitra has split 2 times.

How Many Employees Does Azitra Have?

Azitra has 13 employees.

What is the current trading status of Azitra (AZTR)?

As of Jun 14, 2026, Azitra (AZTR) is trading at a price of 0.2117 USD, with a previous close of 0.2210 USD. The stock has fluctuated within a day range of 0.2116 USD to 0.2211 USD, while its 52-week range spans from 0.1000 USD to 2.3976 USD.

What Is Azitra (AZTR) Price Target According to Analysts?

The average 12-month price target for Azitra is 0.7750 USD, with a high estimate of 1 USD and a low estimate of 0.55 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +266.08% Upside potential.

What Is the AZTR Premarket Price?

AZTR's last pre-market stock price is 0.2155 USD. The pre-market share volume is 9,030.0000, and the stock has decreased by -0.0055, or -2.4900%.

What Is the AZTR After Hours Price?

AZTR's last after hours stock price is 0.2060 USD, the stock has decreased by -0.0057, or -2.6900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.